Elbit proposes to complete purchase of Elscint
This article was originally published in Clinica
Executive Summary
Elbit Medical Imaging, the holding company for Elscint, wants to buy up all Elscint shares in an offer worth about $99 million. Elbit already holds a 57% stake in Elscint, and has offered stockholders $14 a share, a 21% premium over the closing price registered on the New York Stock Exchange before the proposal was made on February 17.